Fingerprint
Dive into the research topics of 'Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).
Amanda Cashen, Mark Juckett, Alcee Jumonville, Mark Litzow, P. J. Flynn, John Eckardt, Betsy LaPlant, Kristina Laumann, Charles Erlichman, John DiPersio
Research output: Contribution to journal › Article › peer-review
48
Scopus
citations